Graft-versus-host reaction following blood product transfusion

Fliedner, V von; Higby, Donald J.; Kim, Untae

doi:10.1016/0002-9343(82)90857-9

Cited by 166 publications

(44 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most commonly, GVHD is seen in patients who have been rendered immunoincompetent by total body irradiation or cytotoxic drugs [3], especially in patients receiving marrow transplants from HLA-identical siblings [4]. In addition, blood transfusion related GVHD usually develops in patients with an impaired immune system [8]. …”

Section: Discussionmentioning

confidence: 99%

A Case of Chronic Graft-versus-Host Disease following Living-Related Donor Kidney Transplantation

Ohtsuka¹,

Sakemi²,

Ichigi³

et al. 1998

Nephron

View full text Add to dashboard Cite

A 25-year-old man with a 2.5-year history of maintenance hemodialysis underwent a living-related donor (father) kidney transplantation. He was free from acute rejection, but 8 months after the kidney transplantation, he complained of malaise and fever which were accompanied by eruptions on the face, fingers, and hips which resembled symptoms seen in patients suffering from systemic vasculitis. Skin biopsy findings were compatible with those of chronic graft-versus-host disease (GVHD). The human leukocyte antigen (HLA) family study disclosed that the donor’s HLA haplotype was homozygous and identical to one of the recipient’s HLA haplotypes which indicated that the host would not resist engraftment. On the basis of these findings, a diagnosis of chronic GVHD was made, and increasing doses of immunosuppressants resulted in a resolution of these symptoms. Our report is the first describing GVHD that developed in a patient undergoing related-donor kidney transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Chronic Graft-versus-Host Disease following Living-Related Donor Kidney Transplantation

Ohtsuka¹,

Sakemi²,

Ichigi³

et al. 1998

Nephron

View full text Add to dashboard Cite

show abstract

“…1,2 Initially described as erythroderma accompanied by rapidly fatal pancytopenia in immunodeficient patients, the syndrome was subsequently characterized as a form of GVHD following blood transfusion. 3,4 Over the past three decades, the pathophysiology of TA-GVHD has been studied extensively, and the primary mechanism of action attributed to the proliferation of donor T cells in susceptible recipients following transfusion. 5 By empirical experience, irradiation of blood components with either gamma or Xray sources has been established as an effective means to prevent TA-GVHD.…”

mentioning

confidence: 99%

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Corash

Lin

2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy. Currently, cellular blood components for patients recognized at risk for TA-GVHD are irradiated prior to transfusion in order to prevent this complication. Considerable progress has been made in elucidating the pathophysiology of this highly morbid complication, but questions as to which patients are at risk and what is the most robust technology to prevent TA-GVHD remain. As new technologies for inactivating or modulating leukocyte function are introduced, the question of how to evaluate these technologies becomes relevant. Over the past two decades, a number of research groups have explored technology to inactivate infectious pathogens and leukocytes contaminating cellular blood components. Few clinicians have an in-depth understanding of the methods or the criteria for selection of how to approach new technologies for leukocyte inactivation with potential to replace current methods. This mini review focuses on the salient aspects of current and evolving technology for prevention of TA-GVHD.

show abstract

“…6 In later years, a form of GVHD-(transfusion-associated GVHD, or TA-GVHD)-was recognized in immunocompromised patients following nonirradiated, nonrelated-donor blood product transfusions. 7 In 1989, a group of Israeli cardiac surgeons observed postoperative erythroderma in 2 immunocompetent patients who received HLA homozygous whole-blood transfusions, but because the histology of the skin lesions was very similar to previously described GVHD histology, they stated that postoperative erythroderma is a skin manifestation of GVHD and that GVHD could also occur in immunocompetent patients who received transfusions of nonirradiated blood products from HLA-homozygous donors for 1 of the recipient's haplotypes. 8 PATHOGENESIS OF TA-GVHD Transfused T lymphocytes are the cause of TA-GVHD, wherein it is believed that both CD4 þ and CD8 þ T lymphocytes play critical roles.…”

Section: History Of Gvhdmentioning

confidence: 86%

Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future

Bahar¹,

Tormey

2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Transfusion-associated graft-versus-host disease (TA-GVHD) is a disease with a very high mortality rate. In this report, we discuss TA-GVHD from a historical perspective, highlight the pathogenesis of TA-GVHD, and emphasize the importance of blood product irradiation, which is a very effective means to prevent this disease. We summarize the current recommendations in different patient populations from different countries and review recent developments, such as alternatives for the use of radioactive materials. We also speculate on future directions.

show abstract

Graft-versus-host reaction following blood product transfusion

Cited by 166 publications

References 52 publications

A Case of Chronic Graft-versus-Host Disease following Living-Related Donor Kidney Transplantation

A Case of Chronic Graft-versus-Host Disease following Living-Related Donor Kidney Transplantation

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future

Contact Info

Product

Resources

About